Sera Prognostics (SERA) Return on Capital Employed (2021 - 2026)
Sera Prognostics (SERA) posted Return on Capital Employed of 49.27% for Q1 2026, down 9.1% on a QoQ basis from 45.16% in Q4 2025, and up 184.0% year-over-year from 17.35% in Q1 2025.
Sera Prognostics (SERA) Return on Capital Employed (2021 - 2026) Analysis & Trends
Sera Prognostics' Return on Capital Employed history runs 6 years deep, the most recent figure standing at 49.27% for Q1 2026.
- Quarterly Return on Capital Employed rose 184.0% year-over-year to 49.27% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 49.27% (up 184.0% YoY) and the FY2025 annual result came in at 57.88%, up 396.0% from the prior year.
- Return on Capital Employed was 49.27% for Q1 2026 at Sera Prognostics, down from 45.16% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 31.1% in Q1 2022 and bottomed at 71.81% in Q4 2024.
- A 5-year average of 49.31% and a median of 49.27% in 2026 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2022 — Return on Capital Employed sank 2031 bps — and 2025, when it soared 2665 bps.
- Sera Prognostics' Return on Capital Employed stood at 45.24% in 2022, then retreated by 29 bps to 58.3% in 2023, then dropped by 23 bps to 71.81% in 2024, then soared by 37 bps to 45.16% in 2025, then declined by 9 bps to 49.27% in 2026.
- Business Quant data shows SERA's Return on Capital Employed at 49.27% in Q1 2026, 45.16% in Q4 2025, and 42.75% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | 9.61% |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 12.24% |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 8.02% |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | 9.62% |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | 11.13% |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 24.24% |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | 9.30% |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 8.38% |
| 10 | Sera Prognostics | 105.54 Mn | 105.54 Mn | -28,000.00 | -49.27% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -49.27% |
| Dec 31, 2025 | -45.16% |
| Sep 30, 2025 | -42.75% |
| Jun 30, 2025 | -40.32% |
| Mar 31, 2025 | -51.11% |
| Dec 31, 2024 | -71.81% |
| Sep 30, 2024 | -62.44% |
| Jun 30, 2024 | -56.51% |
| Mar 31, 2024 | -55.20% |
| Dec 31, 2023 | -58.30% |
| Sep 30, 2023 | -51.85% |
| Jun 30, 2023 | -51.05% |
| Mar 31, 2023 | -45.98% |
| Dec 31, 2022 | -45.24% |
| Sep 30, 2022 | -42.61% |
| Jun 30, 2022 | -37.53% |
| Mar 31, 2022 | -31.10% |
| Dec 31, 2021 | -24.94% |
| Sep 30, 2021 | -22.84% |